Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial. - Publication

Publication

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.

Journal Paper/Review - Jun 18, 2022

van Heek Lutz, Stuka Colin, Kaul Helen, Müller Horst, Mettler Jasmin, Hitz Felicitas, Baues Christian, Fuchs Michael, Borchmann Peter, Engert Andreas, Dietlein Markus, Voltin Conrad-Amadeus, Kobe Carsten

Citation

van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin C, Kobe C. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial. BMC cancer 2022; 22:672.

Type

Journal Paper/Review (English)

Journal

BMC cancer 2022; 22

Publication Date

Jun 18, 2022

Issn Electronic

1471-2407

Pages

672

Brief description/objective

F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with early stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD16 trial.